Blood Advances · 2025 · 14 citations · 10 references
MedicineOphthalmologyPharmacologyClinical PharmacologyOcular OncologyOcular PharmacologyDose Adjustment In OncologyVisual Loss EvaluationAdverse Ocular EffectsDose Delay ManagementEye IrritationMultiple Myeloma ChemotherapyMultiple Myeloma TherapyOphthalmic Clinical ExaminationRefractory Multiple MyelomaRelapsed Multiple Myeloma
ABSTRACT: Belantamab mafodotin (belamaf) combined with standard therapies demonstrated significant progression-free survival (PFS) and overall survival benefits in DREAMM-7 and PFS benefit in DREAMM-8 in relapsed/refractory multiple myeloma. Belamaf dose modifications managed adverse events, including belamaf-related ocular events. Ocular events included ocular adverse reactions (eg, dry eyes, photophobia, eye irritation) and protocol-mandated ophthalmic examination findings. Protocol-recommended dose modifications for ocular events were driven by ophthalmic examination findings and included belamaf dose delays until resolution and reductions. We used descriptive analyses to evaluate the impact of dose modifications on managing ocular events and treatment efficacy. In patients with normal baseline vision who were receiving treatment, dose modifications extended belamaf dosing intervals to a median of 8 to 12 weeks by 9 months; the prevalences of reduced vision to bilateral 20/50 or worse and ocular adverse reactions were highest in the first 3 months and remained low at later time points. The median time to resolution after grade ≥2 ophthalmic examination findings was 12 weeks. Rates of belamaf discontinuations due to ocular events were low. Almost all responders (partial response or better) required dose modifications. Most patients achieved a response before an extended (>2 cycles) dose delay; most who had not, subsequently achieved or deepened their response. In DREAMM-7 and DREAMM-8, the median PFS in patients with ≥1 dose delay of ≥12 weeks was 36.6 months and not reached, respectively. Ocular events were common but effectively managed with dose modifications, allowing for patients to remain on treatment and derive robust efficacy benefit. The trials were registered at www.clinicaltrials.gov as #NCT04246047 (DREAMM-7) and #NCT04484623 (DREAMM-8).
10
A Confidence Interval for the Median Survival Time
Ron Brookmeyer, John Crowley · Biometrics · 1982 · 908 citations
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat et al. · Ophthalmology and Therapy · 2020 · 176 citations · Full text
Medicine, Oncology, Pharmacology +15
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations
Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · Cancer · 2021 · 143 citations · Full text